AB 1474 directs California’s Health Care Cost Transparency Board to set a statewide per‑capita health care cost target and to create more granular targets by sector, region, and—where appropriate—by individual health care entity. The bill charges the board’s office with developing a transparent methodology, directing public reporting, and building in adjustments for factors such as population risk, equity, geographic cost differences, workforce stability, and rapidly rising costs (notably prescription drugs and nonsupervisory organized labor).
The law aims to make spending growth predictable and to pressure high‑cost parts of the system while preserving quality and access. For regulated payers the bill also creates targets on administrative costs and profits, and it requires data submissions and public reporting so policymakers and purchasers can see which sectors and entities drive cost growth.
At a Glance
What It Does
The office must develop a public, transparent methodology for annual per‑capita cost targets; the board adopts statewide targets and may set sector, region, and entity targets informed by historical cost, quality, and workforce data. The methodology explicitly allows adjustments for risk, equity, geographic cost differences, organized labor cost growth, and prescription drug price growth, and includes special treatment of pandemic years and Medi‑Cal funding issues.
Who It Affects
Fully integrated delivery systems, commercial and public payers, individual hospitals and provider groups that qualify as high‑cost outliers, and entities participating in Medi‑Cal and the Health Care Payments Data Program. The board and its office will also need resources to collect, audit, and publish the required data.
Why It Matters
This is a regulatory lever to constrain system‑wide spending growth rather than relying solely on rate setting or market competition. By combining entity‑level targets, public reporting, and adjustments for labor and drug pressures, the bill creates new accountability pathways for payers and large systems—and new compliance and reporting obligations for providers and insurers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 1474 creates a two‑layer regime: a statewide per‑capita spending target and the ability to tailor targets by sector, region, or individual entity when appropriate. The office must propose a methodology that the board approves; the methodology has to be public and must draw on historical spending, economic indicators, and population demographics.
It also requires separate consideration of the anomalous 2020–2021 years because of COVID‑19’s impact on utilization and spending.
The bill builds in a range of technical adjustments. Risk‑adjustment methodology is required so targets can reflect patient mix and health status; equity adjustments must account for social determinants and other validated measures; and geographic cost adjustments reflect differences in labor and operating costs across communities.
The office can convene technical committees, rely on existing models, and audit submissions where upcoding or data issues are suspected.Two specific upward/downward adjustment pathways are prominent. First, the office must allow target increases for entities that demonstrate higher prescription drug cost growth, and for entities with documented increases in nonsupervisory organized labor costs; those requests must be made in an office‑prescribed format and may be audited.
Second, the board can lower targets for entities that deliver high‑cost care without commensurate quality gains and raise targets for low‑cost, high‑quality entities—using reported cost and quality data from the Health Care Payments Data Program and other state and federal sources.The bill also treats fully integrated delivery systems (FIDS) differently: until sector targets are in place they must comply with the statewide target; once sector targets are adopted, FIDS are subject to targets for each separately administered geographic service area and must submit comparable data across lines of business and payer types. Payers face additional constraints because the legislation establishes administrative cost and profit targets and requires coordination with regulators that oversee actuarial soundness and rate review.
Finally, the bill mandates public performance reporting (statewide, by region, by market and line of business, and for individual entities both unadjusted and risk‑adjusted) and makes the 2025 baseline a reporting year only, with enforceable targets beginning in 2026.
The Five Things You Need to Know
The 2025 target is a reporting baseline only; enforceable targets begin for the 2026 calendar year.
The board must publish proposed cost targets by March 1 of the year prior to the applicable target year, accept 45 days of public comment, and adopt final targets on or before June 1.
The office’s methodology must treat 2020 and 2021 differently because of COVID‑19’s distortion of prior spending patterns.
Providers or integrated systems can request target adjustments for projected nonsupervisory organized labor cost growth and must submit supporting documentation (the office may audit submissions).
Adoption of cost targets under AB 1474 is explicitly exempted from the Administrative Procedure Act, so the board’s final targets are not subject to the usual state rulemaking procedures.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Statewide health care cost target established
Subsection (a) creates the board’s core duty: establish a statewide health care cost target. Practically, this is the top‑level spending ceiling against which later, more granular targets and analyses are calibrated. The language provides the legal hook for the board to oversee statewide spending growth without specifying a particular target formula in statute.
Sector, regional, and entity targets; adjustment authority
Subdivision (b) requires the board to define sectors (which may include geographic regions and individual entities) and to set targets by sector, region, and, where appropriate, individual entities; it also permits later adjustments to reflect baseline differences. The mechanics matter: the board can avoid one‑size‑fits‑all rules by setting different expectations for, say, rural hospitals or an FIDS operating across multiple markets—subject to the office’s sector definitions and rules.
Principles and goals for targets
Subdivision (c) lays out the policy constraints: targets must promote predictable per‑capita spending growth, be transparent, be updated annually (with multiyear consideration), preserve quality and equity, and support workforce stability. These statutory criteria will guide how the office weighs trade‑offs—e.g., whether a target is tightened despite workforce instability concerns.
Methodology development, data inputs, and Medi‑Cal considerations
Subdivision (d) directs the office to design a public methodology for setting targets, reviewing economic indicators, and using historical spending across Medi‑Cal, Medicare, and commercial coverage. The text explicitly allows special handling of 2020–21 and requires the methodology to consider nonfederal shares, supplemental payments, taxes, and other Medi‑Cal funding mechanics so that targets do not jeopardize federal matching funds—an important operational protection for state‑federal financing.
Entity‑level target methods: risk, equity, and geography
Subdivision (e) sets out how individual entity targets should be set: offering pathways to identify high‑cost outliers and to incentivize serving higher‑risk populations by using risk‑factor, equity, and geographic cost adjustments. This creates a structure for softer, data‑driven relief for providers serving sicker, poorer, or higher‑cost communities.
Risk adjustment technical framework
Subdivision (f) requires the office, in consultation with the board, to adopt transparent risk‑adjustment methods and allows technical committees. It also instructs the office to guard against perverse incentives like upcoding and authorizes audits and periodic methodological updates—giving the office tools to maintain the integrity of comparisons across providers.
Payer administrative‑cost and profit targets
Subdivision (h) directs the office to set targets on payers’ administrative costs and profits to deter growth in those areas and ties adjustments to the medical loss ratio so administrative targets cannot simply expand when medical expenses exceed targets. The office must consult DMHC, DHCS, and the Department of Insurance so actuarial soundness and rate review obligations are accounted for.
Treatment of fully integrated delivery systems
Subdivision (i) requires FIDS to comply initially with the statewide target and later subjects them to geographic‑service‑area targets; it also requires FIDS to submit comprehensive, comparable data across services, lines of business, and payer types to enable transparent performance comparisons and public reporting.
Timeline, public process, and meetings
Subdivision (l) sets the 2025 reporting baseline, makes 2026 the first enforceable year, and gives the board deadlines to define sectors and adopt sector targets (Oct 1, 2027 and June 1, 2028, respectively). Subdivision (m) prescribes a public process: office recommendations posted online, a board discussion by March 1 prior to the target year, a 45‑day public comment window, and final adoption by June 1—meetings subject to Bagley‑Keene. Those deadlines create a predictable annual cadence for target-setting.
Rulemaking exemption and exempted providers
Subdivision (n) exempts adoption of targets from the Administrative Procedure Act, accelerating the board’s ability to adopt targets without formal rulemaking. Subdivision (p) lets the board define exempted providers by regulation but clarifies that payer‑reported spending on those providers must still be counted in total health care expenditures—closing a potential loophole where an exempt provider’s costs could be excluded from system calculations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers and large purchasers — The law aims to slow per‑capita spending growth and increases transparency on which sectors drive costs, which can give employers, purchasers, and consumer advocates leverage to demand better value.
- Low‑cost, high‑quality providers — The board can set upward adjustments or favorable treatment for entities demonstrably delivering low‑cost, high‑quality care, which creates incentives and potential public recognition for efficient providers.
- State agencies and policymakers — Consolidated, public reporting on contributions to cost growth gives policymakers better evidence to design interventions, allocate resources, and coordinate Medi‑Cal financing without relying on fragmented data.
- Workforce and training programs — The statute explicitly requires consideration of workforce stability and graduate medical education in target design; that creates an explicit statutory voice for workforce investments during target-setting.
Who Bears the Cost
- Payers (insurers and managed care plans) — New limits on administrative costs and profits plus requirements to submit granular data, with potential public accountability and corrective action, raise compliance costs and could compress margins.
- Large provider systems and FIDS — Subject to sector and service‑area targets, required to submit comprehensive data and potentially face downward target adjustments or enforcement for excess cost growth; compliance and reporting will require staff time and systems investments.
- Individual providers and small hospitals — Although risk and equity adjustments exist, smaller entities may struggle to meet data collection, auditing, and documentation demands needed to justify adjustments, imposing operational and financial burdens.
- The board and the office — The statute creates substantial analytic, audit, and reporting work that the board’s staff must perform; unless matched with funding, the agency will face resource constraints and potential implementation delays.
Key Issues
The Core Tension
The statute’s central dilemma is familiar: impose enforceable limits to restrain spending growth and hold high‑cost actors accountable, while ensuring targets don’t reduce access, undermine quality, or destabilize the workforce—especially in communities with higher clinical and social needs. Any strong cost constraint risks squeezing providers’ margins, prompting service reduction or consolidation; any generous adjustments to protect access dilute cost control. The bill tries to thread that needle with risk, equity, workforce, and drug‑cost adjustments, but the trade‑offs are real and hinge on how accurate, auditable, and well‑resourced the methodologies and enforcement processes become.
AB 1474 centralizes a complex measurement task: comparing per‑capita spending across heterogeneous providers, payers, and regions. That invites methodological controversy.
Risk and equity adjustments are necessary to avoid penalizing providers serving high‑need populations, but developing validated, auditable adjustments is technically demanding and expensive. The statute authorizes audits and technical committees, but it does not specify funding for those activities, raising questions about the office’s capacity to execute rigorous audits and maintain the data infrastructure.
The bill reduces procedural friction by exempting target adoption from the Administrative Procedure Act, which speeds decisions but narrows procedural protections and public challenge avenues. The law also requires careful coordination with Medi‑Cal financing to avoid jeopardizing federal matching funds; that constraint could blunt the board’s flexibility and create a political back‑and‑forth between state fiscal priorities and federal requirements.
Finally, enforcement mechanics are referenced by cross‑citation but are not detailed in §127502 here; without clear, proportional enforcement tools, targets may become aspirational rather than binding for some entities, or enforcement could be uneven and legally contested.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.